Somatostatin receptor agonists and antagonists

Bibliography

• BRAZEAU P, VALE W, BURGUS R et al: Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science (1973) 179:77–79.
   PubMed Web of Science ®Google Scholar
• DE LECEA L, CRIADO JR, PROSPERO-GARCIA O et al: A cortical neuropeptide with neuropeptide with neuronal depressant and sleep-modulating properties. Nature (1996) 381:242–245.
   PubMed Web of Science ®Google Scholar
• SPIER AD, DE LECEA L: A member of the somatostatin neuropeptide family with distinct physiological functions. Brain Res. Rev (2000) 33(2,3):228–241.
   Google Scholar
• FUKUSUMI S, KITADA C, TAKEKA S et al.: Identification and characterization of a novel human cortistatin-like peptide. Biochem. Biophys. Res. Commun. (1997) 232:157–163.
   PubMed Web of Science ®Google Scholar
• SIEHLER S, SEUWEN K, HOYER D: P25II-Tyr10-cortistatin labels all five somatostatin receptors. Naunyn Schmiedebergs Arch. Pharmacol (1998) 375(5):483–489.
   Google Scholar
• PUEBLA L, MOUCHANTAF R, SASI R et al.: Processing of rat preprocortistatin in mouse AtT-20 cells. Neurochem. (1999) 73:1273–1277.
   PubMed Web of Science ®Google Scholar
• DEGHENGHI R, PAPOTTI M, GHIGO E, MUCCIOLI G: Cortistatin, but not somatostatin, binds to growth hormone secretagoue (GSH) receptors of human pituitary. I Endocrinol Invest. (2001) 24:RC1-RC3.
   Google Scholar
• DALM VA, VAN HAGEN MP, VAN KOETSVELD PM et al.: Cortistatin rather than somatostatin as a potential ligand for somatostatin receptors in the human immune system. J. Clin. Endocrinol Metabol (2003) 88:270–276.
   Google Scholar
• •Data presented indicating that CST may be the endogenous ligand at sst2 in the human immune system.
   Google Scholar
• HOYER D, BELL GI, BERELOWITZ M et al.: Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci. (1995) 16:86–88.
   PubMed Web of Science ®Google Scholar
• BELL GI, REISINE T: Molecular biology of somatostatin receptors. Trends Neurosci (1993) 16:34–38.
   PubMed Web of Science ®Google Scholar
• HANNON JP, NUNN C, STOTZ B et al: Drug design at peptide receptors. Neurosci. (2002) 18:15–27.
   Web of Science ®Google Scholar
• •A review of SRIF and SRN' receptor ligands.
   Google Scholar
• PNVKO C, THOSS VS, PROBST A, HOYER D: Localization and pharmacological characterization of somatostatin recognition sites in the human cerebellum. Neurophannacology (1996) 35:713–723.
   PubMed Web of Science ®Google Scholar
• SCHINDLER M, KIDD EJ, CARRUTHERS AM et al: Molecular cloning and functional characterization of a rat somatostatin 55t2B receptor splice variant. Br. j Pharmacol (1998) 125:209–217.
   PubMed Web of Science ®Google Scholar
• SARRET P, GOTTO JM, VINCENT JP, MAZELLA J, BEAUDET A: Preferential expression of sst2A over 55t2B somatostatin receptor splice variant in rat brain and pituitary. Neuroendocrinology (1998) 68:37–43.
   PubMed Web of Science ®Google Scholar
• PATEL YC: Molecular pharmacology of somatostatin receptor subtypes. .1. Endocrinol Invest. (1997) 20:348–367.
   PubMed Web of Science ®Google Scholar
• PATEL YC, GREENWOOD MT, PANETTA R, DEMCHYSHYN L, NIZNIK H, SRIKANT CB: The somatostatin receptor family: a mini review. Life Sci. (1995) 57:1249–1265.
   PubMed Web of Science ®Google Scholar
• PATEL YC: Somatostatin and its receptor family. Frontiers Neuroendocrinol (1999) 20:157–158.
   PubMed Web of Science ®Google Scholar
• MURTHY KS, COY DH, MAKHOULF G: Somatostatin receptor mediated signaling in smooth muscle. Biol. Chem. (1996) 271:23458–23463.
   Google Scholar
• SCHWEITZER R, MADAMBE S, SIGGINS GR: Arachidonic acid metabolites as mediators of somatostatin-induced increase of neuronal m-current. Nature (1990) 346:464–467.
   PubMed Web of Science ®Google Scholar
• PFEIFFER M, KOCH T, SCHODER H et al.: Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst3 receptor function by heterodimerization with sst2A. J. Biol. Chem. (2001) 276:14027–14036.
   Google Scholar
• PFEIFFER M, KOCH T, SCHRODER H,LAUGSCH M, HOLLT V, SCHULZ S: Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. I Biol. Chem. (2002) 277:19762–19772.
   Web of Science ®Google Scholar
• BREDER CD, YAMADA YY, YASUDA K et al.: Differential expression of somatostatin receptor subtypes in brain. Neurosci. (1992) 12:3920–3924.
   Web of Science ®Google Scholar
• KONG H, DE PAOLI AM, BRED ER CD, YASUDA K, BELL GI, REISINE T: Differential expression of messenger RNA's for somatostatin receptor subtypes SSTR1, SSTR2 and SSTR3 in adult rat brains: analysis by RNA blotting and in situ hybridization histochemistry. Neuroscience (1994) 59:175–184.
   PubMed Web of Science ®Google Scholar
• THOSS VS, PEREZ J, DUC D, HOYER D: Embryonic and postnatal mRNA distribution of five receptor subtypes in rat brain. Neuropharmacology (1995) 34:1673–1688.
   PubMed Web of Science ®Google Scholar
• DAY R, DONG W, PANETTA R, KRAICER J, GREENWOOD MT, PATEL YC: Expression of mRNA for somatostatin receptor (sstr) Types 2 and Sin individual rat pituitary cells. A double labeling in situ hybridization analysis. Endocrinology (1995) 136:5232–5235.
   PubMed Web of Science ®Google Scholar
• HOYER D, LUBBERT H, BRUNS C: Molecular pharmacology of somatostatin receptors. Naunyn Schnnedebergs Arch. Pharinacol (1994) 350:441–453.
   Google Scholar
• LE ROMANCER M, CHERIFI Y, LAVASSEUR S et al.: Messenger RNA expression of somatostatin receptor subtypes in human and gastric mucosae. Life Sci. (1996) 58:1091–1098.
   PubMed Web of Science ®Google Scholar
• BRUNO JF, XU Y, SONG J, BERELOWITZ M: Tissue distribution of somatostatin receptor subtype messenger ribonucleic acid in rat. Endocrinology (1993) 133:2561–2567.
   PubMed Web of Science ®Google Scholar
• CURTIS SB, HEWITT J, YAKUBOVITZ S, ANZARUT A, HSIANG YN, BUCHAN AM: Somatostatin receptor subtype expression and function in human vascular tissue. Ain. J. Physiol (2000) 278:1815–1822.
   PubMed Web of Science ®Google Scholar
• BATES CM, KEGG H, PETREVSKI C, GRADY S: Expression of somatostatin receptors 3, 4, and 5 in mouse kidney proximal tubules. Kidney Int. (2003) 63:53–63.
   PubMed Web of Science ®Google Scholar
• LIU S, CRIDER AM, TANG C, HO B, ANKERSEN M, STIDSEN CE: 2-Pyridylthioureas: novel non-peptide somatostatin agonists with sst4 selectivity. Cuir. Med. Chem. (1999) 6:401–410.
   Google Scholar
• CULLER MD, TAYLOR JE, MOREAU JP: Somatostatin receptor subtypes: targeting functional and therapeutic specifity. Ann. Endocrina (2002) 63(2Part3):255–2512.
   Google Scholar
• STROWSKI MZ, PARMAR RM, BLAKE AD, SCHAEFFER JM: Somatostatin inhibits insulin and glucagon secretion via two receptor subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology (2000) 141:111–117.
   PubMed Web of Science ®Google Scholar
• •Data presented showing that insulin secretion was mediated via ssts, whereas glucagon release was regulated by sst2.
   Google Scholar
• STROWSKI MZ, KOHLER M, CHEN HY et al.: Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis. Ma Endocrinol (2003) 17:93–106.
   PubMed Web of Science ®Google Scholar
• STROWSKI MZ, DASHKEVICZ MP, PARMAR RM et al.: Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells. Neuivendocrinology(2002) 75:339–346.
   PubMed Web of Science ®Google Scholar
• DRUCKER DJ: Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology (2002) 122:531–544.
   PubMed Web of Science ®Google Scholar
• STARK A, ROLF M: Somatostatin inhibitsglucagon-like peptide-1 induced insulin secretion and proliferation of R1Nm5F insulinoma cells. Regal. Pept. (2002) 108:97–102.
   PubMed Web of Science ®Google Scholar
• CHISHOLM C, GREENBERG GR: Somatostatin-28 regulates GLP-1 secretion via somatostatin receptor subtype 5 in rat intestinal cultures. Am. I Physic] (2002) 283: (2Part1):E311–E317.
   Google Scholar
• DI VITO L, BROGLIO F, BENSO A et al.:The GH-releasing effect of ghrelin, a natural GH secretagogue, is only blunted by the infusion of exogenous somatostatin in humans. Clin. Endocrinol (2002) 56:643–648.
   PubMed Web of Science ®Google Scholar
• BROGLIO F, VAN KOELSVELD P, BENSON A et al.: Ghrelin secretion is inhibited by either somatostatin or cortistatin in humans. I Gin. Endocrinol Metabol (2002) 87:4829–4832.
   PubMed Web of Science ®Google Scholar
• VASILAK A, GEORGOUSSI Z, THERMOS K: Somatostatin receptors (sst2) are coupled to G. and modulate GTPase activity in rabbit retina. Neurochem. (2003) 84:625–632.
   Google Scholar
• DAL MONTE M, PETRUCCI C, COZZI A, ALLEN JP, BAGNOLI P: Somatostatin inhibits potassium-evoked release by activation of sst2 somatostatin receptor in mouse retina. Naunyn Schmiebergs Arch. Pharmacol (2003) 367:186–192.
   Google Scholar
• VASILAKI A, MOURATIDOU M, SCHULZ S, THERMOS K: Somatostatin mediates nitric oxide production by activating sst2 receptors in rat retina. Neuropharmacology (2002) 43:899–909.
   PubMed Web of Science ®Google Scholar
• REUBI JC, WASER B, SCHAERJC, LAISSUE JA: Somatostatin receptor ssti - ssts expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur: I Nucl. Med. (2001) 28:836–846.
   PubMedGoogle Scholar
• TEIJEIRO R, RIOS R, COSTOYA J et al.: Activation of human somatostatin receptor 2 promotes apotosis through a mechanism that is independent from induction of p53. Cell Physiol Biochem. (2002) 12:31–38.
   PubMed Web of Science ®Google Scholar
• HALL GH, TURNBULL LW, RICHMOND I, HELBOE L, ATKIN SL: Localization of somatostatin and somatostatin receptors in benign and malignant ovarian tumors. Br. I Cancer (2002) 87:86–90.
   PubMed Web of Science ®Google Scholar
• HANSSON J, BJARTELL A, GADALEANU V, DIZEYI N, ABRAHAMSSON PA: Expression of somatostatin receptor subtype 2 and 4 in human benign prostatic hyperplasia and prostatic cancer. Prostate (2002) 53:50–59.
   PubMed Web of Science ®Google Scholar
• LUTHERMAN K, HACKSELL U: Chapter 14. Peptides and peptidomimetics. In: A Textbook of Drug Design and Development. Krogsgaard-Larsen P, Lilejefors T, Madsen U (Eds), Harwood Academic Publishers, Amsterdam (1996):386–406.
   Google Scholar
• VALE W, RIVIERJ, LING N, BROWN M: Biologic and immunologic activities and applications of somatostatin analogues. Metabolism (1978) 27:1392–1401.
   Web of Science ®Google Scholar
• VEBER DF, SAPERSTEIN R, NUTT RF et al.: Super active hexapeptide analogues of somatostatin. Life Sci. (1984) 34:1371–1378.
   PubMed Web of Science ®Google Scholar
• BAUER W, BRINER U, DOEPFNER W et al.: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. (1982) 31:1133–1140.
   PubMed Web of Science ®Google Scholar
• LIAPAKIS G, HOEGER C, RIVIER J, REISINE T: Development of a selective agonist at the somatostatin receptor subtype Pharmacol. Exp. Ther. (1996) 276:1089–1094.
   PubMed Web of Science ®Google Scholar
• RIVIER JE, HOEGER C, ERCHEGYI J et al.: Potent undecapeptide agonists selective for somatostatin receptor 1 (ssti). Med. Chem. (2001) 44:2238–2246.
   Web of Science ®Google Scholar
• •Report on des-amino acid (1,2,5)-SRIF analogues having high affinity for ssti.
   Google Scholar
• RAJESWARAN WG, HOCART SJ, MURPHY WA, TAYLOR JE, COY DH: N-Methyl scan of somatostatin octapeptide agonists produces interesting effects on receptor subtype specificity.' Med. Chem. (2001) 44:1416–1421.
   Web of Science ®Google Scholar
• AFARGAN M, JANSON ET, GELERMAN G et al.: Novel long-acting somatostatin analogues with endocrine selectivity: potent suppression of growth hormone but not insulin. Endocrinology (2001) 142(1):477–486.
   PubMed Web of Science ®Google Scholar
• •Data presented to show that PTR-3173 selectively inhibited GH release compared to insulin or glucagon release.
   Google Scholar
• GAZAL S, GELERMAN G, ZIV O et al.: Human somatostatin receptor specificity of backbone-cyclic analogues containing novel sulfur building units. I Med. Chem. (2002) 45:1665–1671.
   PubMed Web of Science ®Google Scholar
• GADEMANN K, KIMMERLIN T, HOYER D, SEEBACH D: Peptide folding induces high and selective affinity of a linear and small 3-peptide to the human somatostatin receptor 4.j Med. Chem. (2001) 44:2460–2468.
   PubMed Web of Science ®Google Scholar
• REUBI JC, EISENWIENER KP, RINK H,WASER B, MACKE HR: A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. Lim Pharmacol (2002) 456:45–49.
   Web of Science ®Google Scholar
• SEEBACH D, SCHAEFFER L, BRENNER M, HOYER D: Design and synthesis of 7-dipeptide derivatives with submicromolar affinities for human somatostatin receptors. Angew. Chem. mt. Ed. (2003) 42:776–778.
   Google Scholar
• •Report on y-dipeptides as metabolically stable peptidomimetics of SRIF.
   Google Scholar
• BASS RT, BUCKWALTER BL, PATEL BP et al.: Indentification and characterization of novel somatostatin antagonists. Ma Pharmacol (1996) 50:709–715.
   PubMed Web of Science ®Google Scholar
• HOCART SJ, JAIN R, MURPHY WA, TAYLORJE, MORGAN B, COY DH: Potent antagonists of somatostatin: synthesis and biology." Med. Chem. (1998) 41:1146–1154.
   PubMed Web of Science ®Google Scholar
• HOCART SJ, JAIN R, MURPHY WA, TAYLOR JE, COY DH: Highly potent cyclic disulfide antagonists of somatostatin. Med. Chem. (1999) 42:1863–1871.
   Web of Science ®Google Scholar
• RAJESWAN WG, HOCART SJ, MURPHY WA, TAYLOR JE, COY DH: Highly potent and subtype selective ligands derived by N-methyl scan of a somatostatin antagonist. Med. Chem. (2001) 44:1305–1311.
   Web of Science ®Google Scholar
• ••Systematic N-methyl scan of SRIF analogues to obtain sst2, sst3, and ssts antagonists.
   Google Scholar
• RAJESWAN WG, MURPHY WA, TAYLOR JE, COY DH: Exploration of the D-Trp-N-MeLys motif in the search for potent somatostatin antagonists. Bioorg. Med. Chem. (2002) 10:2023–2030.
   PubMed Web of Science ®Google Scholar
• REUBI JC, SCHAER JC, WENGER S et al.: sst3-Selective potent peptidic somatostatin receptor antagonists. Proc. Natl. Acad. Sci. USA (2000) 97:13973–13978.
   PubMed Web of Science ®Google Scholar
• NUNN C, SCHOEFFTER P, LANGENEGGER D, HOYER D: Functional characterization of the putative somatostatin sst2 receptor antagonist CYN-154806. Naunyn Schmiedeberg's Arch. Pharmacol (2003) 367:1–9.
   Google Scholar
• •Re-evaluation of the putative sst2 antagonist CYN–154806.
   Google Scholar
• CRIDER AM: Recent advances in the development of non-peptide somatostatin receptor ligands. Mini Rev Med. Chem. (2002) 2:507–517.
   PubMed Web of Science ®Google Scholar
• •Review on SRIF and SRIF receptor ligands.
   Google Scholar
• HIRSCHMANN R, NICOLAOU K, PIETRANICO S et al.: Non-peptidal peptidomimetics with P-D-glucose scaffolding. A partial somatostatin agonist bearing a close structural relationship to a potent, selective substance P antagonist. Am. Chem. Soc. (1992) 114:9217–9218.
   Google Scholar
• HIRSCHMANN R, HYNES J Jr, CICHY-KNIGHT MA et al.: Modulation of receptor and receptor subtype affinities using diastereomeric and enantiomeric monosaccharide scaffolds as a means to structural and biological diversity. A new route to ether synthesis. Med. Chem. (1998) 41:1382–1391.
   Google Scholar
• PRASAD V, BIRZIN ET, MC VAUGH CT et al.: Effects of heterocyclic aromatic substituents on binding affinities at two sites of somatostatin (SRIF) receptors. Correlation with electrostatic potential of the substituents. Med. Chem. (2003) 46:1858–1869.
   Google Scholar
• ••D-Glucose-derived non-peptides with highaffinity for sst4.
   Google Scholar
• ANKERSEN M, CRIDER M, LIU S, HO B, ANDERSEN HS, STIDSEN C: Discovery of a novel non-peptide somatostatin agonist with 55T4 selectivity. Am. Chem. Soc. (1998) 120:1368–1373.
   Web of Science ®Google Scholar
• LIU S, TANG C, HO B, ANKERSEN M, STIDSEN CE, CRIDER AM: Non-peptide somatostatin agonists with sst4 selectivity: synthesis and structure-activity relationships of thioureas.j. Med. Chem. (1998) 41:4693–4705.
   PubMed Web of Science ®Google Scholar
• YANG L, GUO L, PASTERNAK A et at Spiro [1 Hindene- 1, 4'-piperidine] derivatives as potent and selective non-peptide human somatostatin receptor subtype 2 (sst2) agonists. Med. Chem. (1998) 41:2175–2179.
   Web of Science ®Google Scholar
• ROHRER SP, BIRZIN ET, MOSLEY RT et al.: Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science (1998) 282:737–740.
   PubMed Web of Science ®Google Scholar
• ••This paper describes the discovery of SRIFnon-peptide analogues at all ssts.
   Google Scholar
• BERK SC, ROHRER SP, DEGRADO SJ et al.: A combinatorial approach toward the discovery of non-peptide subtype-selective somatostatin receptor ligands. J. Comb. Chem. (1999) 1:388–396.
   PubMedGoogle Scholar
• YANG L, BERK SC, ROHRER SP et a/.: Synthesis and biological evaluation of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc. Natl. Acad. Sit USA (1998) 95:10836–10841.
   Google Scholar
• PASTERNAK A, PAN Y, MARINO D et al.: Potent, orally-bioavailable somatostatin agonists: good absorption achieved by urea backbone cyclization. Bioorg. Med. Chem. Lett. (1999) 9:491–496.
   PubMed Web of Science ®Google Scholar
• SOUERS AJ, VIRGILLO AA, ROSENQUIST A et al.: Identification of a potent heterocyclic ligand to somatostatin receptor subtype 5 by synthesis and screening of 13-turn mimetic libraries.' Am. Chem. Soc. (1999) 121:1817–1825.
   Google Scholar
• GALCERA-CONTOUR MO, POITOUT L, MOINET C et al: Synthesis of imidazopyrazines as ligands for the human somatostatin receptor subtype 5. Bioorg. Med. Chem. Lett. (2001) 11:741–745.
   PubMed Web of Science ®Google Scholar
• MOINET C, CONTOUR-GALCERA MO, POITOUT L et al.: Novel non-peptide ligands for the somatostatin sst3 receptor. Bioorg. Med. Chem. Lett. (2001) 11:991–996.
   PubMed Web of Science ®Google Scholar
• LIU J, UNDERWOOD DJ, CASCIERI MA et al.: Synthesis of a substance P antagonist with a somatostatin scaffold: factors affecting agonism/antagonism at GPCRs and the role pseudosymmetry. I Med. Chem. (2000) 43:3827–3831.
   PubMed Web of Science ®Google Scholar
• HAY BA, COLE BM, DICAPUA F et al: Small molecule somatostatin receptor subtype 2 antagonists. Bioorg. Med. Chem. Lett. (2001) 11:2731–2734.
   PubMed Web of Science ®Google Scholar
• ••This paper reports the first non-peptide sst2 antagonist.
   Google Scholar
• NUNN C, LANGENEGGER D, HURTH K, SCHMIDT K, FEHLMANN D, HOYER D: Agonist properties of putative small-molecule somatostatin sst2 receptor-selective antagonists. Eur. Pharmacol (2003) 465:211–218.
   PubMed Web of Science ®Google Scholar
• ••Re-evaluation of putative sst2 antagonists.These analogues were shown to have sst2 agonist activity and affinity for sst5 receptors.
   Google Scholar